Topotecan hydrochloride studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 104864/032 | IV | An open label evaluation of topotecan administered intravenously as five daily 30 minute infusions every 21 days to patients with ovarian tumours refractory to other therapies |
| 104864/039 | III | An Open-Label, Multicenter, Randomized, Phase III Study of Topotecan HCl as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Taxolâ (Administered as a Three-Hour Infusion Every 21 Days) in Women With Advanced Epithelial Ovarian Carcinoma |
| 104864/067/080 | III | An Open-Label, Multicenter, Randomized, Phase III, Comparative Study of Topotecan, as Single Agent, Second-Line Therapy Administered Intravenously or Orally as Five Daily Doses Every 21 Days in Women with Advanced Ovarian Cancer |
| 104864/096 | III | An open-label, multicentre, randomised, phase III study of topotecan plus cisplatin versus paclitaxel plus cisplatin for the first-line treatment of patients with advanced ovarian carcinoma. |
| 104864/396 | III | An open-label, multicentre, randomised, phase III comparator study of oral topotecan versus intravenous topotecan for second-line therapy in patients with SCLC who have relapsed greater than or equal to 90 days after completion of first-line therapy |
| 104864/A/090 | III | An Open Label, Multicenter, Randomized, Phase III Study of Hycamtin (Topotecan) as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Second-Line Cyclophosphamide, Doxorubicin and Vincristine (CAV) in Patients with SCLC Who Have Relapsed At Least 60 Days After Completion of First-Line Therapy. |
| 104864/A201 | III | A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS |
| HCT103369 (GOG-0179) | III | A randomized phase III study of cisplatin versus cisplatin plus topotecan versus methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the cervix. |
| SKF-104864/615 | III | An Open-Label, Multicenter, Randomized, Phase III Study Comparing Combination Intravenous (IV) Topotecan/Docetaxel to Docetaxel Alone in Second-Line Advanced (IIIB/IV) Non-Small-Cell Lung Cancer (NSCLC) |
| 104864/012 | II | An Open Phase Ii Study To Evaluate The Efficacy And Toxicity Of Topotecan Administered Intravenously As Five Daily Infusions Every 21 Days To Women With Advanced Epithelial Ovarian Carcinoma |
| 104864/014 EORTC | II | A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC) |
| 104864/015 | II | An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer |
| 104864/033 | II | An open, multicenter, Phase II study of intravenous topotecan, given as five daily doses every 21 days, in advanced epithelial ovarian cancer to patients who have failed prior chemotherapy containing paclitaxel and cisplatin or carboplatin |
| 104864/034 | II | An open, multicentre, Phase II study of intravenous topotecan, given as 5 daily doses every 21 days, in advanced epithelial ovarian cancer |
| 104864/051 | II | An Open, Non-Comparative, Phase II Study of Topotecan Given as a Continuous 21-Day Infusion Every 28 days, to Women with Advanced Epithelial Ovarian Cancer who have failed One Prior Chemotherapy Regimen Containing Cisplatin or Carboplatin |
| 104864/053 | II | An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer |
| 104864/057 | II | An Open-Label, Non-Comparative, Phase II Study of Topotecan as Single Agent, First-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Stage IIIB and IV Non-Small Cell Lung Cancer. |
| 104864/059 | II | An Open-label, Non-Comparative, Phase II Study of Topotecan as Single Agent, Second-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Relapsed or Refractory Small Cell Lung Cancer |
| 104864/065 | II | An open-label multicentre, randomised, phase II comparator study of oral topotecan versus intravenous topotecan for second-line therapy in sensitive patients with small cell lung cancer |
| 104864/092 | II | Phase II trial with topotecan in patients with small cell lung cancer. |
| 104864/094 | II | EORTC 08957: A phase II trial of Topotecan in combination with Cisplatin as second line treatment in small cell lung cancer (SCLC) |
| 104864/181 | II | Phase II Study of Topotecan in Patients with Extensive Small Cell Lung Cancer |
| 104864/251 | II | A phase II study to determine the efficacy and safety of topotecan administered intravenously daily for 5 days with a single intravenous dose of carboplatin on Day 1 repeated every 21 days in patients with advanced non-small cell lung cancer |
| 104864/373 | II | A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered every 21 Days to Patients with Epithelial Ovarian Cancer Stages IIb, IIc, III and IV |
| 104864/410 | II | A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer |
| 104864/435 | II | A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer |
| 104864/557 | II | A Phase II Trial Of Topotecan and Cisplatin In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of The Cervix |
| 104864/627 | II | An open-label, multicenter, non-comparative, phase II study of the combination of intravenous topotecan and gemcitabine administered once weekly for three weeks every 28 days as second-line treatment in subjects with recurrent platinum-sensitive ovarian cancer |
| 104864/A405 | II | An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer |
| 104864-A/213 | II | An Open-label Evaluation of Topotecan Administered Intravenously as Five Daily 30 Minute Infusions every 21 days to Patients with Ovarian Tumors Refractory to Other Therapies. |
| SK&F104864/111 | II | An Open, Comparative, Phase II Study of Immediate Versus Delayed Treatment with Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients with AIDS-Related Progressive Multifocal Leukoencephalopathy. |
| SK&F-104864-623 | II | An Open Label, Multicenter, Non-Comparative Phase II Study of Weekly Intravenous Vinorelbine and Topotecan in Chemotherapy-Naďve Patients with Advanced Non-Small Cell Lung Cancer |
| SKF-104864/234 | II | Phase II Trial of Topotecan Combined With Cisplatin in Persistent or Recurrent Squamous and Non-squamous Cervical Cancer |
| SKF-104864/612 | II | A prospective, open label phase II study to evaluate the efficacy and safety of topotecan (Hycamtin) in combination with carboplatin as first-line chemotherapy in patients with ovarian cancer. |
| 104864/005 | I | Phase I study of topotecan |
| 104864/010 | I | An Open Phase I Study to Determine the Maximal Tolerated Dose of Topotecan HCl Administered Intravenously as a Single Dose Every 21 Days in Patients with Solid Tumors Refractory to All Known Forms of Effective Therapy |
| 104864/017 | I | A Phase I Study of Topotecan HCl Administered on a Daily Times Five Schedule with a Single Infusion of Cisplatin every Three Weeks to Patients with Advanced Non-small Cell Lung Carcinoma |
| 104864/178 | I | A Phase I study to assess the safety and tolerability of Hycamtin administered sequentially to patients with cancer of the ovary who have received carboplatin and Taxol treatment. |
| 104864/A097 | I | Phase I Study of Topotecan in Cancer Patients with Hepatic or Renal Dysfunction |
| SK&F104864/100 | I | A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma. |
| SK&F-104864/517 | I | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Subjects with Rectal Carcinoma |
| SKF 104864/191 | I | Phase I study with Hycamtin® (topotecan) and simultaneous radiation in subjects with non-small cell lung cancer (NSCLC) stage IIIb. |